Professor Ziwei HUANG
Professor Huang Ziwei graduated from the South China Normal University in 1986 and received his Ph.D from University of California, San Diego, CA. Professor Huang is a well-known scientist in the international biomedical field. He has made breakthroughs in biochemical medicine in the past 20 years, and has developed a variety of new drugs for the treatment of human immune system diseases, cancer and AIDS. Professor Huang maintains a world leading position in the field of new drug research for these diseases.
Chemical Biology, Biochemistry and Structural Biology, Genomics and Proteomics, Stem Cell and Regenerative Medicine, Systems Biology and Pharmacology, Translational Medicine
Cancer, Neurological disorders, Autoimmune diseases, AIDs and Other Infectious Diseases, New Drug Discovery, Medicinal Chemistry, Peptide Chemistry, New Drug Design and Development, Computer-aided Drug Design, High-throughput Screening, Peptide and Small Molecule Design and Synthesis, Nanomedicine
1、 Krieg A, Correa RG, Garrison JB, Negrate GL, Welsh K, Huang Z, Knoefel WT and Reed JC. XIAP mediates NOD signaling via interaction with RIP2. Proc. Natl. Acad. Sci. USA, 2009, 106:14524-9.
2、 Hu Q, Nie A, Welsh K, Crisóstomo FR, Zhu X, Li Z, An J, Reed JC, Zhang L and Huang Z*. Novel XIAP inhibitors as probes of apoptosis in biology and medicine. Exp. Biol. Med., 2011, 236:247-51.
3、 Choi WT, Kumar S, Madani N, Tian S, Dong CZ, Liu D, Yuan J, Sodroski JG, Huang Z* and An J. A novel synthetic bivalent ligand to probe chemokine receptor CXCR4 dimerization and inhibit HIV-1 entry. Biochemistry, 2012, 51:7078-86.
4、 Xu Y, Duggineni S, Espitia S, Richman DD, An J, and Huang Z*. A synthetic bivalent ligand of CXCR4 inhibits HIV infection. Biochem. Biophys. Res. Commun., 2013, 435:646-50.
5、 Duggineni S, Mitra S, Noberini R, Han X, Lin N, Xu Y, Tian W, An J, Pasquale EB, and Huang Z*. Design, synthesis and characterization of novel small molecular inhibitors of Ephrin-B2 binding to EphB4. Biochem. Pharmacology, 2013, 85:507-13.